FDA has expanded the approval of Zelboraf (vemurafenib), a kinase inhibitor, to include the treatment of certain adult patients with Erdheim-Chester Disease, a rare blood cancer. Zelboraf is indicated to treat patients whose cancer cells have a specific genetic mutation known as BRAF V600. This is the first FDA-approved treatment for ECD.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
